Home » Stocks » PRGO

Perrigo Company PLC (PRGO)

Stock Price: $43.71 USD -0.94 (-2.11%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 5.97B
Revenue (ttm) 5.10B
Net Income (ttm) -6.60M
Shares Out 136.50M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE 10.38
Dividend $0.90
Dividend Yield 2.06%
Trading Day January 15
Last Price $43.71
Previous Close $44.65
Change ($) -0.94
Change (%) -2.11%
Day's Open 44.72
Day's Range 43.50 - 45.20
Day's Volume 2,426,233
52-Week Range 40.13 - 59.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 1 week ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider bu...

Other stocks mentioned: HHC, PRTY, CODI, CQP, HOME, WRLD
Forbes - 1 week ago

We believe that Perrigo stock, a healthcare company that provides over-the-counter health and wellness solutions, is a good buying opportunity at the present time. PRGO stock trades near $45 c...

Zacks Investment Research - 1 month ago

Let's see if Perrigo Company plc (PRGO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Zacks Investment Research - 1 month ago

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 2 months ago

In its journey to become a consumer-led player, Perrigo has already achieved its long-term sales targets well ahead of the schedule. Partly helped by pandemic-driven changes to consumer habits...

Insider Monkey - 2 months ago

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our i...

The Motley Fool - 2 months ago

Investors liked the company's third-quarter earnings results.

Zacks Investment Research - 2 months ago

Perrigo (PRGO) reports decent third-quarter 2020 results. U.S. consumer self-care segment drives sales.

The Motley Fool - 2 months ago

The healthcare company delivered both good news and bad news.

Seeking Alpha - 2 months ago

Perrigo Company plc (PRGO) CEO Murray Kessler on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Perrigo (PRGO) delivered earnings and revenue surprises of 10.71% and -1.44%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 2 months ago

DUBLIN, Nov. 4, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that the Irish High Court, which is a court of first instance, ruled that the issuance of the Notice...

PRNewsWire - 2 months ago

DUBLIN, Nov. 2, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, announced today that it has completed the acqu...

PRNewsWire - 2 months ago

DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it has been advised by the Iris...

Zacks Investment Research - 2 months ago

Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.

Zacks Investment Research - 2 months ago

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 2 months ago

DUBLIN, Oct. 22, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced that its Board of Directors d...

PRNewsWire - 3 months ago

DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it will release its third quart...

Investopedia - 3 months ago

These are the healthcare stocks with the best value, fastest growth, and most momentum for October 2020.

Other stocks mentioned: BIIB, BIO, CVS, IMMU, LVGO, MRNA, PODD, QDEL
Market Watch - 4 months ago

Perrigo Company plc shares PRGO, -0.16% slid 3% in premarket trade Thursday, after the company said it's voluntarily recalling albuterol sulfate inhalation aerosols over concerns that some may...

PRNewsWire - 4 months ago

DUBLIN, Sept. 17, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced a voluntary U.S.

Investopedia - 4 months ago

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: AZN, BIIB, MNTA, NLTX, RLMD, SNY, SUPN, TAK
Zacks Investment Research - 4 months ago

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 4 months ago

DUBLIN, Ireland, Aug. 25, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced that CEO and Preside...

Seeking Alpha - 5 months ago

Perrigo Company plc (PRGO) CEO Murray Kessler on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Perrigo (PRGO) reports decent second-quarter 2020 results. The addition of products following Ranir acquisition boosts sales in the quarter.

Zacks Investment Research - 5 months ago

Perrigo (PRGO) delivered earnings and revenue surprises of 18.39% and -0.69%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 5 months ago

Shares of Perrigo (NYSE:PRGO) rose 0.9% in pre-market trading after the company reported Q2 results.

Zacks Investment Research - 5 months ago

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 6 months ago

Rotation offers opportunity in top stocks and industries.

Other stocks mentioned: BEP, BLL, COST, DE, MMC, PG, TGT, WCN
Zacks Investment Research - 6 months ago

Medical Products Industry's Near-Term Outlook Lacks Spark

Other stocks mentioned: ABT, BAX, BSX, HRC, ISRG, MDT, RMD, SYK, ZBH
Benzinga - 7 months ago

Perrigo Company PLC (NYSE: PRGO), one of the world’s largest producers of over-the-counter self-care products, is entering the CBD business.

Zacks Investment Research - 7 months ago

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 8 months ago

PRGO can effectively and cost efficiently produce generic drugs, competing with brand names.

Seeking Alpha - 8 months ago

Perrigo Company plc (PRGO) CEO Murray Kessler on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Perrigo (PRGO) reports decent first-quarter 2019 results. The addition of products following Ranir acquisition and stock piling due to COVID-19 boosts sales in the quarter.

Zacks Investment Research - 8 months ago

Perrigo (PRGO) delivered earnings and revenue surprises of 4.59% and 1.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 8 months ago

Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.

Zacks Investment Research - 8 months ago

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Other stocks mentioned: DXCM, HAE
Zacks Investment Research - 8 months ago

Perrigo (PRGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CNBC Television - 9 months ago

Pharmaceuticals company Perrigo CEO says 'all trends are heading toward self-care'

errigo CEO Murray Kessler in a "Mad Money" interview discusses trends in the health-care industry and "transforming ourselves to a self-care company."

Zacks Investment Research - 9 months ago

Perrigo (PRGO) announces better-than-expected preliminary results for first-quarter 2020. Shares gain.

Market Watch - 9 months ago

Perrigo Co. PRGO, -1.03% said late Tuesday it experienced a first-quarter sales boost due to the COVID-19 pandemic.

Zacks Investment Research - 9 months ago

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 10 months ago

Medical Products Industry Outlook: Growth Prospects Bright

Other stocks mentioned: ABT, BAX, BSX, HRC, ISRG, MDT, RMD, SYK, ZBH
Zacks Investment Research - 10 months ago

Perrigo (PRGO) reports mixed fourth-quarter 2019 results. The addition of products following Ranir acquisition boosts sales in the quarter.

Seeking Alpha - 10 months ago

Perrigo Company plc (PRGO) CEO Murray Kessler on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Perrigo (PRGO) delivered earnings and revenue surprises of -2.75% and 0.71%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Market Watch - 10 months ago

Perrigo Co. PLC PRGO, +0.00% reported Thursday a fourth-quarter adjusted profit that came up shy of expectations while sales were in line, while providing a downbeat full-year earnings outlook.

Benzinga - 10 months ago

Perrigo Co (NYSE: PRGO) announces its next round of earnings this Thursday, February 27.

About PRGO

Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health,... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Dec 16, 1991
CEO
Murray Kessler
Employees
11,000
Stock Exchange
NYSE
Ticker Symbol
PRGO
Full Company Profile

Financial Performance

In 2019, Perrigo's revenue was $4.84 billion, an increase of 2.23% compared to the previous year's $4.73 billion. Earnings were $146.10 million, an increase of 11.53%.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for Perrigo stock is "Buy." The 12-month stock price forecast is 56.22, which is an increase of 28.62% from the latest price.

Price Target
$56.22
(28.62% upside)
Analyst Consensus: Buy